4.2 Article

The burden of pathogenic variants in clinically actionable genes in a founder population

Journal

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
Volume 185, Issue 11, Pages 3476-3484

Publisher

WILEY
DOI: 10.1002/ajmg.a.62472

Keywords

exome sequencing; founder populations; genetic testing; genomic medicine; secondary findings

Funding

  1. Regeneron Genetics Center
  2. University of Maryland School of Medicine Program for Personalized and Genomic Medicine

Ask authors/readers for more resources

Founder populations like the Lancaster Amish exhibit higher frequencies of specific pathogenic genetic variants compared to nonfounder populations, offering opportunities for more efficient precision medicine interventions.
Founder populations may be enriched with certain genetic variants of high clinical impact compared to nonfounder populations due to bottleneck events and genetic drift. Using exome sequencing (ES), we quantified the load of pathogenic variants that may be clinically actionable in 6136 apparently healthy adults living in the Lancaster, PA Old Order Amish settlement. We focused on variants in 78 genes deemed clinically actionable by the American College of Medical Genetics and Genomics (ACMG) or Geisinger's MyCode Health Initiative. ES revealed 3191 total variants among these genes including 480 nonsynonymous variants. After quality control and filtering, we applied the ACMG/AMP guidelines for variant interpretation and classified seven variants, across seven genes, as either pathogenic or likely pathogenic. Through genetic drift, all seven variants, are highly enriched in the Amish compared to nonfounder populations. In total, 14.7% of Lancaster Amish individuals carry at least one of these variants, largely explained by the 13% who harbor a copy of a single variant in APOB. Other studies report combined frequencies of pathogenic/likely pathogenic (P/LP) variants in actionable genes between 2.0% and 6.2% in outbred populations. The Amish population harbors fewer actionable variants compared to similarly characterized nonfounder populations but have a higher frequency of each variant identified, offering opportunities for efficient and cost-effective targeted precision medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available